Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
2.160
-0.170 (-7.30%)
At close: Jul 17, 2026, 4:00 PM EDT
2.100
-0.060 (-2.78%)
After-hours: Jul 17, 2026, 7:59 PM EDT
Cadrenal Therapeutics Employees
Cadrenal Therapeutics had 5 employees as of December 31, 2025. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$2,377,704
Market Cap
6.20M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 1 | 25.00% |
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 1 | 33.33% |
| Dec 31, 2022 | 3 | - | - |
| Sep 30, 2022 | 1 | - | - |
| Jun 30, 2022 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| BioAtla | 41 |
| CollPlant Biotechnologies | 39 |
| Aptevo Therapeutics | 33 |
| Processa Pharmaceuticals | 12 |
| Purple Biotech | 10 |
| Adial Pharmaceuticals | 5 |
| XTL Biopharmaceuticals | 5 |
CVKD News
- 6 days ago - Cadrenal Therapeutics files to sell 2.94M shares of common stock for holders - TheFly
- 6 days ago - Cadrenal Therapeutics announces clinical data from CAD-1005 study - TheFly
- 6 days ago - Cadrenal Therapeutics' Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress - GlobeNewsWire
- 6 days ago - Cadrenal Therapeutics Registration statement: Registration filing - Filings
- 19 days ago - Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 25 days ago - Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress - GlobeNewsWire
- 4 weeks ago - Cadrenal Therapeutics to file for FDA RPDD for tecarfarin in Kawasaki Disease - TheFly
- 4 weeks ago - Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease - GlobeNewsWire